Behind the headlines

30 November 2018
Autumn 2018

Dr David Robert Grimes looks at the eye health issues that are making the news.

/COO/media/Media/Acuity/Autumn 2018/Behind-headlines-avastin-CREDIT-Alamy-600x400_1.jpg

NHS to save millions on AMD treatment

A landmark ruling promises to substantially reduce the cost of treating wet age-related macular degeneration (AMD) – and has significant implications for future drug policy. Bayer and Novartis had attempted to stop clinical commissioning groups (CCGs) from prescribing Avastin – a widely used and cheaper treatment, but unlicensed for AMD.

In September, the High Court ruled against the drug giants. 

Sign in to continue

Forgotten password?

Not already a member of The College?

Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

Related further reading

The latest edition of Acuity, the College’s professional journal, is now available in print and online.

In our latest podcast, we speak to Professor Gilmartin and Mr Kam Balaggan, Consultant Ophthalmologist, about the battle to save his remaining vision.


The role of optometrist in the detection and management of AMD in the UK and Australia.